Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer

被引:44
作者
Yigit, Refika [1 ]
Figdor, Carl G. [2 ]
Zusterzeel, Petra L. M. [1 ]
Pots, Jeanette M. [2 ]
Torensma, Ruurd [2 ]
Massuger, Leon F. A. G. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol 791, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Tumour Immunol, Nijmegen Ctr Mol Life Sci 278, NL-6500 HB Nijmegen, Netherlands
关键词
Ovarian cancer; Immune suppression; Cytokines; Ascites; IL-6; REGULATORY T-CELLS; AUTOCRINE GROWTH-FACTOR; IMMUNE-RESPONSES; CARCINOMA CELLS; FACTOR-BETA; IN-VITRO; INTERLEUKIN-6; IL-6; B7-H4; MICROENVIRONMENT;
D O I
10.1016/j.ejca.2011.03.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian cancer (EOC) is an immunogenic tumour and exploits many suppressive ways to escape immune eradication. EOC is known to spread primarily by tumour cell implantations in peritoneal cavity. Therefore, ascites may be an ideal fluid compartment to unravel the immune status of the peritoneal cavity. We analysed the expression of IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IFN-gamma, TNF-alpha, TNF-beta, TGF-beta and CCL22 in ovarian cancer ascites, representing immune activating and suppressing cytokines. We observed high expression of pro-inflammatory cytokines IL-6, IL-8 and immune suppressive cytokines IL-10, CCL22 and TGF-beta in most samples whereas Th1 (IL-12p70, IFN-gamma) and Th2 (IL-4, IL-5) cytokines were only detectable in 13% of the samples. TGF-beta was only detected in latent form, questioning its immune suppressive role. CCL22 was in similar levels present in early stage compared to advanced stage tumours. At advanced stage, we observed a negative correlation with CCL22 levels and Th1/2 cytokine expression. We found a positive correlation between IL-6 concentration in ascites and residual disease after debulking. Additionally, IL-6 levels were remarkably higher at recurrence compared to primary advanced disease, which opens an opportunity for inhibition of IL-6 expression in the prevention of recurrence. Despite the heterogeneity of EOC and the complexity of cytokine functions, our results show that cytokine analysis in ascites may aid in understanding tumour host interaction in EOC. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1883 / 1889
页数:7
相关论文
共 42 条
[1]  
[Anonymous], INT J CANC
[2]  
Barillé S, 2000, EUR CYTOKINE NETW, V11, P546
[3]   ROLE OF INTERFERONS AND OTHER CYTOKINES IN THE REGULATION OF THE IMMUNE-RESPONSE [J].
BELARDELLI, F .
APMIS, 1995, 103 (03) :161-179
[4]   Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma [J].
Chen, Li-li ;
Ye, Feng ;
Lue, Wei-guo ;
Yu, Yan ;
Chen, Huai-zheng ;
Xie, Xing .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2009, 35 (02) :212-218
[5]   Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer [J].
Curiel, TJ ;
Cheng, P ;
Mottram, P ;
Alvarez, X ;
Moons, L ;
Evdemon-Hogan, M ;
Wei, S ;
Zou, LH ;
Kryczek, I ;
Hoyle, G ;
Lackner, A ;
Carmeliet, P ;
Zou, WP .
CANCER RESEARCH, 2004, 64 (16) :5535-5538
[6]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[7]   The two faces of IL-6 on Th1/Th2 differentiation [J].
Diehl, S ;
Rincón, M .
MOLECULAR IMMUNOLOGY, 2002, 39 (09) :531-536
[8]  
Giuntoli RL, 2009, ANTICANCER RES, V29, P2875
[9]  
GOLDBERG JE, 2010, CURR DRUG TARGETS
[10]   Active TGF-β1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence [J].
Hawinkels, Lukas J. A. C. ;
Verspaget, Hein W. ;
van der Reijden, Johan J. ;
van der Zon, Johanna M. ;
Verheijen, Jan H. ;
Hommes, Daniel W. ;
Lamers, Cornelis B. H. W. ;
Sier, Cornelis F. M. .
CANCER SCIENCE, 2009, 100 (04) :663-670